| Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs CJH Porter, NL Trevaskis, WN Charman Nature reviews Drug discovery 6 (3), 231-248, 2007 | 1919 | 2007 |
| Strategies to address low drug solubility in discovery and development HD Williams, NL Trevaskis, SA Charman, RM Shanker, WN Charman, ... Pharmacological reviews 65 (1), 315-499, 2013 | 1590 | 2013 |
| From sewer to saviour—targeting the lymphatic system to promote drug exposure and activity NL Trevaskis, LM Kaminskas, CJH Porter Nature reviews Drug discovery 14 (11), 781-803, 2015 | 542 | 2015 |
| Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update NL Trevaskis, WN Charman, CJH Porter Advanced drug delivery reviews 60 (6), 702-716, 2008 | 454 | 2008 |
| 50 years of oral lipid-based formulations: provenance, progress and future perspectives OM Feeney, MF Crum, CL McEvoy, NL Trevaskis, HD Williams, ... Advanced drug delivery reviews 101, 167-194, 2016 | 347 | 2016 |
| The mechanisms of pharmacokinetic food-drug interactions–A perspective from the UNGAP group M Koziolek, S Alcaro, P Augustijns, AW Basit, M Grimm, B Hens, CL Hoad, ... European Journal of Pharmaceutical Sciences 134, 31-59, 2019 | 270 | 2019 |
| Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review Z Vinarov, M Abdallah, JAG Agundez, K Allegaert, AW Basit, ... European Journal of Pharmaceutical Sciences 162, 105812, 2021 | 151 | 2021 |
| Sex-specific adipose tissue imprinting of regulatory T cells A Vasanthakumar, D Chisanga, J Blume, R Gloury, K Britt, DC Henstridge, ... Nature 579 (7800), 581-585, 2020 | 144 | 2020 |
| From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases EH Pilkington, EJA Suys, NL Trevaskis, AK Wheatley, D Zukancic, ... Acta biomaterialia 131, 16-40, 2021 | 143 | 2021 |
| Lipid-based formulations and drug supersaturation: harnessing the unique benefits of the lipid digestion/absorption pathway HD Williams, NL Trevaskis, YY Yeap, MU Anby, CW Pouton, CJH Porter Pharmaceutical research 30, 2976-2992, 2013 | 116 | 2013 |
| Targeted delivery of a model immunomodulator to the lymphatic system: comparison of alkyl ester versus triglyceride mimetic lipid prodrug strategies S Han, T Quach, L Hu, A Wahab, WN Charman, VJ Stella, NL Trevaskis, ... Journal of Controlled Release 177, 1-10, 2014 | 85 | 2014 |
| Intestinal bile secretion promotes drug absorption from lipid colloidal phases via induction of supersaturation YY Yeap, NL Trevaskis, T Quach, P Tso, WN Charman, CJH Porter Molecular pharmaceutics 10 (5), 1874-1889, 2013 | 83 | 2013 |
| A new in vitro lipid digestion – in vivo absorption model to evaluate the mechanisms of drug absorption from lipid-based formulations MF Crum, NL Trevaskis, HD Williams, CW Pouton, CJH Porter Pharmaceutical research 33, 970-982, 2016 | 68 | 2016 |
| Targeted drug delivery to lymphocytes: a route to site-specific immunomodulation? NL Trevaskis, WN Charman, CJH Porter Molecular pharmaceutics 7 (6), 2297-2309, 2010 | 67 | 2010 |
| Lipid absorption triggers drug supersaturation at the intestinal unstirred water layer and promotes drug absorption from mixed micelles YY Yeap, NL Trevaskis, CJH Porter Pharmaceutical research 30, 3045-3058, 2013 | 62 | 2013 |
| Methotrexate-conjugated PEGylated dendrimers show differential patterns of deposition and activity in tumor-burdened lymph nodes after intravenous and subcutaneous … LM Kaminskas, VM McLeod, DB Ascher, GM Ryan, S Jones, JM Haynes, ... Molecular pharmaceutics 12 (2), 432-443, 2015 | 60 | 2015 |
| The lymph lipid precursor pool is a key determinant of intestinal lymphatic drug transport NL Trevaskis, CJH Porter, WN Charman Journal of Pharmacology and Experimental Therapeutics 316 (2), 881-891, 2006 | 57 | 2006 |
| Lymphatic targeting by albumin-hitchhiking: applications and optimisation M Abdallah, OO Müllertz, IK Styles, A Mörsdorf, JF Quinn, MR Whittaker, ... Journal of Controlled Release 327, 117-128, 2020 | 55 | 2020 |
| Glyceride‐mimetic prodrugs incorporating self‐immolative spacers promote lymphatic transport, avoid first‐pass metabolism, and enhance oral bioavailability L Hu, T Quach, S Han, SF Lim, P Yadav, D Senyschyn, NL Trevaskis, ... Angewandte Chemie 128 (44), 13904-13909, 2016 | 55 | 2016 |
| Mesenteric lymphatic dysfunction promotes insulin resistance and represents a potential treatment target in obesity E Cao, MJ Watt, CJ Nowell, T Quach, JS Simpson, V De Melo Ferreira, ... Nature metabolism 3 (9), 1175-1188, 2021 | 54 | 2021 |
Chris PorterDirector, Monash Institute of Pharmaceutical Sciences, Monash UniversityVerified email at monash.edu
